SARS-COV-2 VACCINE SUPPLY AGREEMENT

A Contract Award Notice
by BUSINESS ENERGY AND INDUSTRIAL STRATEGY

Source
Contracts Finder
Type
Contract (Products)
Duration
14.5 month
Value
£1
Sector
HEALTH
Published
12 Feb 2021
Delivery
22 Oct 2020 to 31 Dec 2021
Deadline
21 Oct 2020 23:59

Concepts

Location

Geochart for 1 buyers and 1 suppliers

1 buyer

1 supplier

Description

Procurement of Novavax's vaccine candidate NVX-CoV2373, as intended for the prophylaxis and vaccination against SARS-CoV-2 in humans. Note: This notice corrects and supersedes a previous notice (see links section). It does not represent a new arrangement or contract with the supplier.

Award Detail

1 Novavax (Gaithersburg)
  • Value: £1

CPV Codes

  • 33651600 - Vaccines

Other Information

Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors . Contract end date is being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). The contract end date is variable based on production and delivery of the requirement. There are significant challenges to overcome and the end date may not be a true reflection, setting unrealistic expectation for the public and in the market. This information is also being withheld on due to commercial sensitivity under Regulation 50(6)(b) and (c) as there is significant competition to develop and bring to the market a successful vaccine. Provision of the contract term may provide valuable information to competitors that may impact negotiations or future competition in the market. Sub-contractor details are being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). This information is very sensitive given potential for targeting and disruption of the activities at the facilities which would be contrary to public interest as these activities are critical to success and delivery of the requirement. This link refers to the original notice that is corrected and superseded by this notice https://www.contractsfinder.service.gov.uk/Notice/c1ed715e-9a39-4263-961f-dc8166... SARS-COV2 VACCINE SUPPLY AGREEMENT - [REDACTED] SARS-COV-2 VACCINE SUPPLY AGREEMENT - [REDACTED].pdf

Reference

Domains